Anya Biopharm Inc. (TPEX:7776)

Anya Biopharm Statistics

Total Valuation

Anya Biopharm has a market cap or net worth of TWD 1.90 billion. The enterprise value is 1.51 billion.

Market Cap	1.90B
Enterprise Value	1.51B

Important Dates

The last earnings date was Friday, November 7, 2025.

Earnings Date	Nov 7, 2025
Ex-Dividend Date	n/a

Share Statistics

Anya Biopharm has 49.10 million shares outstanding. The number of shares has increased by 415.67% in one year.

Current Share Class	49.10M
Shares Outstanding	49.10M
Shares Change (YoY)	+415.67%
Shares Change (QoQ)	-0.54%
Owned by Insiders (%)	21.45%
Owned by Institutions (%)	2.96%
Float	27.30M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	76.42
PB Ratio	4.76
P/TBV Ratio	4.84
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-20.14
EV / Sales	60.97
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-23.75

Financial Position

The company has a current ratio of 39.27, with a Debt / Equity ratio of 0.01.

Current Ratio	39.27
Quick Ratio	39.03
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	-0.05
Interest Coverage	-76.64

Financial Efficiency

Return on equity (ROE) is -17.21% and return on invested capital (ROIC) is -6.09%.

Return on Equity (ROE)	-17.21%
Return on Assets (ROA)	-5.86%
Return on Invested Capital (ROIC)	-6.09%
Return on Capital Employed (ROCE)	-10.68%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.05
Inventory Turnover	n/a

Taxes

In the past 12 months, Anya Biopharm has paid 2.36 million in taxes.

Income Tax	2.36M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -2.15% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-2.15%
50-Day Moving Average	42.63
200-Day Moving Average	42.53
Relative Strength Index (RSI)	39.02
Average Volume (20 Days)	51,859

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Anya Biopharm had revenue of TWD 24.83 million and -75.19 million in losses. Loss per share was -1.53.

Revenue	24.83M
Gross Profit	24.69M
Operating Income	-42.84M
Pretax Income	-72.69M
Net Income	-75.19M
EBITDA	-41.68M
EBIT	-42.84M
Loss Per Share	-1.53

Balance Sheet

The company has 386.55 million in cash and 2.94 million in debt, with a net cash position of 383.61 million or 7.81 per share.

Cash & Cash Equivalents	386.55M
Total Debt	2.94M
Net Cash	383.61M
Net Cash Per Share	7.81
Equity (Book Value)	398.50M
Book Value Per Share	8.12
Working Capital	383.09M

Cash Flow

In the last 12 months, operating cash flow was -56.61 million and capital expenditures -7.15 million, giving a free cash flow of -63.77 million.

Operating Cash Flow	-56.61M
Capital Expenditures	-7.15M
Free Cash Flow	-63.77M
FCF Per Share	-1.30

Margins

Gross Margin	99.43%
Operating Margin	-172.52%
Pretax Margin	-292.71%
Profit Margin	n/a
EBITDA Margin	-167.84%
EBIT Margin	-172.52%
FCF Margin	n/a

Dividends & Yields

Anya Biopharm does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-415.67%
Shareholder Yield	-415.67%
Earnings Yield	-3.96%
FCF Yield	-3.36%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Anya Biopharm has an Altman Z-Score of 85.93 and a Piotroski F-Score of 2.

Altman Z-Score	85.93
Piotroski F-Score	2